#United States #New York #Class Action #The Gross Law Firm #Inc. #Merck & Co.

Class Action Class Filed Against Merck & Co., Inc.

On March 17, 2025, the Gross Law Firm announced a class action lawsuit against Merck & Co., Inc. (NYSE: MRK), inviting shareholders who bought shares during a specified period to get in touch about potentially becoming a lead plaintiff. This lawsuit stems from serious concerns regarding the accuracy of revenue expectations set forth by the company concerning its vaccine, Gardasil.

Background of the Case

The class period stretches from February 3, 2022, to February 3, 2025. During this time, Merck executives projected significant future revenue growth from Gardasil, estimating sales of $11 billion by 2030. However, the lawsuit contends that information provided to investors was misleading, implying that Merck could effectively stimulate demand through consumer education initiatives.

The situation took a downturn when, on February 4, 2025, Merck announced it would not reach its previously forecasted sales figure, largely due to a lack of recovery in demand for Gardasil in China. This announcement sent Merck's stock plummeting, falling from $99.79 per share on February 3 to $90.74 on February 4, reflecting a drastic drop of over 9% in just one day.

Shareholder Information

The Gross Law Firm stresses that shareholders should not postpone registering for this class action. The firm has set a deadline of April 14, 2025, for filing claims. Registration involves no costs or obligations and allows shareholders to receive regular updates about the case through a dedicated portfolio monitoring software.

The Gross Law Firm prides itself on advocating for investors who have been harmed due to misleading statements and unethical practices by companies. Their commitment lies in ensuring corporate accountability and protecting shareholder interests against deceit and fraud.

Key Legal Points

• - Class Period: February 3, 2022 - February 3, 2025
• - Allegations: Misleading information regarding Gardasil sales expectations.
• - Stock Impact: Significant price drop post-announcement of revised sales expectations.
• - Next Steps: Interested shareholders should register to receive case updates and explore the option to become a lead plaintiff.

For those looking to navigate these legal waters, the Gross Law Firm offers a straightforward path to involvement and represents a significant ally for aggrieved shareholders. If you purchased shares of MRK during the outlined timeframe, this is your chance to take part in seeking justice.

Contact Information

To register or learn more about the case, shareholders can reach out through the dedicated contact link provided by the Gross Law Firm: Register Here. For more direct inquiries, they can also be contacted at their New York office.

As the April deadline approaches, shareholders are encouraged to act swiftly to preserve their rights and seek a potential recovery for their losses stemming from this massive failure of corporate accountability.